Clinical Trial Search

Primary: Change From Baseline in 24-Hour Average Systolic Ambulatory Blood Pressure to End of Study (EOS) — 2.77; 2.78; 2.15 millimeters of mercury (mmHg)

Primary: Change From Baseline to End of Treatment (EOT) in 24-hour Average Systolic Blood Pressure (SBP) — 1.9 mmHg

Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants

Primary: Brief Pain Inventory (BPI) at Week 14 — 10.2; 9.7; 5.3; 5.1 units on a scale

Primary: Change in Testosterone Levels From Baseline to 27 Weeks — 652 ng/dL

Primary: Percentage of Subjects Achieving a 24 Hour Average Total Serum Testosterone Concentration (Cavg,0-24h) in the Range of 300 to 1050 ng/dL After 15 Days of Treatment With…

Primary: Percentage of Responders — 67; 57; 50; 100 percentage of subjects

Primary: Percentage of Patients With Normalised Testosterone After 24 Weeks of Study Treatment — 59; 62; 63; 7 Participants

Primary: Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion — 12.6; 8.9; 12.8; 3.7 Percent change in muscle strength

Primary: Patient Satisfaction - Change From Baseline — 9.6; 21.5; 18.9; 21.9 Units on a scale

Primary: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene — 3.69; 4.13; 3.82; 0.38 percent change — p=<0.05

Primary: Number of Women Who Came With Their Partners and Received Couple Counseling and Testing — 52; 70 Female participants receiving CHTC

Primary: Incidence of Adverse Events as a Measure of Safety of QuickShot™ Testosterone (QST) Administered Subcutaneously (SC) Once Each Week to Adult Males With Hypogonadism…

Primary: Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range — 78.8 Percentage of Subjects

Primary: Change in Total Morning Testosterone — -16.9; 253.7; 258.5; 197.3 ng/dL